What Patients Report About Ketamine Therapy: Benefits, Challenges, and Uncertainty

Clinical trials tell us about average symptom change. Qualitative studies add a different kind of evidence: how patients describe expectations, the dosing experience, side effects, perceived benefits, disappointments, and what they wish they had known beforehand.

These first-person accounts are useful for preparing patients, but they are not efficacy data and should not be presented as testimonials for Vantage. Individual experiences vary widely, and published qualitative themes do not predict what any particular patient will feel.

A 2025 qualitative meta-synthesis of 24 studies and a 2026 narrative review both found recurring themes around hope and uncertainty before treatment, complex and sometimes distressing acute experiences, perceived changes after treatment, disappointment when treatment did not work or benefits faded, and the importance of clear information and supportive care.

This article summarizes those themes without inventing patient stories or implying that the most dramatic accounts are typical.

A note on route and formulation. Ketamine evidence is route-specific. Much of the controlled antidepressant literature uses intravenous racemic ketamine, while FDA-approved intranasal esketamine (Spravato®) has its own trial program and REMS requirements. Some real-world telehealth studies involve sublingual ketamine. Current Vantage materials describe clinician-guided compounded racemic ketamine nasal spray. That compounded nasal formulation is not FDA-approved for any psychiatric condition, and route-matched controlled evidence is limited. Results from IV, sublingual, or esketamine studies should not be presented as expected outcomes for compounded nasal ketamine.

Before Treatment: Desperation Alongside Cautious Hope

Many participants in qualitative studies described entering ketamine treatment after long and frustrating treatment histories. Hope, caution, skepticism, fear of another disappointment, and uncertainty about the acute experience were all recurring themes.

Those expectations matter to patient experience, but there is no single “normal” emotional starting point. A responsible program should set expectations around both potential benefit and the real possibility of nonresponse or unpleasant acute effects.

Published narratives can help patients feel less alone, but they should not be used to tell a prospective patient how they are supposed to feel before treatment.

During a Session: An Altered State, Not a Recreational High

Depending on dose, route, and individual response, patients may report perceptual changes, altered sense of time or body, emotional distance, sedation, or dissociation during the acute effect. Some experiences are neutral or pleasant; others are uncomfortable or frightening.

Dissociation is a known ketamine and esketamine effect, but its intensity varies and it should not be romanticized as necessary for antidepressant benefit.

Qualitative studies include reports of anxiety, panic, nausea, loss of control, and distressing perceptual or emotional experiences. FDA warnings for ketamine and esketamine also emphasize sedation, dissociation, blood-pressure changes, and misuse risk.

Preparation and support can improve safety and patient comfort, but the optimal psychological-support model has not been established. FDA has specifically warned about compounded ketamine use when adequate monitoring is absent.

Feeling informed, respected, and supported by clinicians is a recurring qualitative theme. That supports patient-centered communication and preparation; it does not establish that the therapeutic relationship accounts for a fixed percentage of ketamine’s antidepressant effect.

The Days After: Improvement, No Change, or Uncertainty

The post-acute period is where patients describe the change they came for, and the language they use is strikingly consistent.

Some patients describe a period of improved mood, reduced rumination, increased motivation, or greater psychological distance from depressive thoughts after treatment. Others report little benefit. Qualitative literature is designed to characterize experience, not estimate how common each outcome is.

Reported positive themes include reduced rumination, improved motivation, better emotional availability, and a renewed sense of possibility. Negative or neutral experiences and nonresponse are also part of the literature and deserve equal visibility.

For some participants, being able to imagine a different future was meaningful. That is a qualitative observation, not a mechanism or outcome that can be promised.

When benefit occurs, its duration varies from brief to more sustained. A fixed “afterglow” duration should not be assumed across routes or patients.

When It Fades: The Part Nobody Advertises

Here is where honest content diverges from marketing content.

Qualitative studies also describe benefit fading for some patients or treatment not working at all. This can be disappointing, especially after a long treatment history, and should be discussed before treatment rather than after expectations have already formed.

The return of symptoms after a period of improvement can feel especially discouraging. Patients should know in advance that rapid improvement does not necessarily mean durable remission.

Expectation-setting is therefore part of responsible informed consent.

Repeated dosing and maintenance are used in some ketamine and esketamine protocols because single-dose benefit may be short-lived. The schedule depends on product, route, indication, evidence base, and response; it should not be generalized as one universal induction series.

Psychotherapy or supportive care may help patients process experiences and address depression through established therapeutic methods. Current systematic reviews do not show consistent controlled evidence that adding psychotherapy to ketamine produces better antidepressant outcomes than ketamine alone, so durability claims should remain modest.

What the Outcome Data Shows

Set against those individual experiences, here is the aggregate picture, stated plainly.

A 2022 meta-analysis of 79 real-world ketamine studies involving 2,665 patients with treatment-resistant depression reported about 45% response and 30% remission on average. Those studies used varied routes and designs. FDA-approved esketamine has separate controlled-trial data. A retrospective at-home sublingual study also reported large symptom reductions, but it was uncontrolled and should not be used as route-matched evidence for compounded intranasal ketamine.

These data support both hope and restraint: meaningful improvement occurs in a substantial subset, while many patients do not reach response or remission. No clinician can predict the result in advance with certainty.

That uncertainty is part of informed consent, not a reason to dismiss the treatment.

What About PTSD?

Ketamine has been studied for PTSD, but the evidence is mixed and it is not FDA-approved for PTSD. Trauma-focused psychotherapies such as Prolonged Exposure and Cognitive Processing Therapy remain established first-line treatments, with EMDR also supported by major guidelines.

Ketamine for PTSD remains an area of active research. A clinician considering it should explain the uncertainty, available first-line treatments, the patient’s co-occurring depression or other conditions, and whether the proposed ketamine route has relevant evidence.

Two Concerns Patients Raise That Deserve Direct Answers

“Will I become dependent on it?” Ketamine is a Schedule III controlled substance with misuse potential. Long-term clinical studies of ketamine and esketamine for depression have not shown high rates of iatrogenic addiction under structured treatment, but monitoring is heterogeneous and risk is not zero. Substance-use history, dose, frequency, home access, and prescribing safeguards all matter.

“Will people judge me for this?” Some patients report stigma because ketamine is also known as a recreational drug. Therapeutic ketamine should be described accurately: racemic ketamine is an established anesthetic used off-label in psychiatry, while esketamine has FDA-approved psychiatric indications. Neither fact guarantees benefit, and a patient has no obligation to disclose treatment beyond what is required for safety, care coordination, or law.

An Honest Invitation

We are not going to tell you that ketamine therapy will change your life. We do not know that, and anyone who claims to know it about a specific patient in advance is not being straight with you.

What the evidence supports is narrower: ketamine and esketamine can produce rapid antidepressant benefit in some patients with difficult-to-treat depression. Response is not universal, durability varies, route matters, and compounded intranasal racemic ketamine has a less developed route-specific evidence base than IV ketamine or FDA-approved esketamine.

A consultation can help determine whether ketamine is a reasonable option, what alternatives exist, and what the treatment would require. The goal is informed choice, not a dramatic promise.

If you are having thoughts of suicide or self-harm, please call or text the 988 Suicide and Crisis Lifeline now. Do not wait for an appointment.

Learn more about ketamine therapy at Vantage

Frequently Asked Questions

What do patients typically experience after a course of ketamine therapy?

Qualitative studies describe a wide range of experiences before, during, and after ketamine treatment. Positive themes can include reduced rumination, improved motivation, and greater psychological flexibility, while negative themes include anxiety, dissociation, unpleasant perceptual effects, disappointment, and nonresponse. These studies characterize lived experience and cannot tell an individual patient what they will feel.

How long does the mood-lifting effect last after ketamine treatment?

When improvement occurs after ketamine, duration varies. Single-dose IV studies often show benefit diminishing over days to weeks, while repeated and maintenance protocols can extend response for some patients. Duration depends on formulation, route, diagnosis, and individual response; there is no universal “afterglow” timeline.

Do patients with treatment-resistant depression achieve lasting remission with ketamine?

Some patients achieve remission and some need repeated or maintenance treatment. A 2022 real-world meta-analysis reported about 30% remission across varied ketamine studies. Durable remission cannot be predicted, and controlled evidence has not established that psychotherapy or integration reliably prolongs ketamine benefit.

What percentage of ketamine therapy patients experience meaningful improvement?

A 2022 meta-analysis of 79 real-world ketamine studies reported about 45% response and 30% remission across varied routes and protocols. FDA-approved esketamine has separate trial data. Observational at-home sublingual studies report additional improvement rates but cannot establish equivalence or predict outcomes for compounded intranasal racemic ketamine.

Can ketamine therapy improve quality of life for PTSD patients?

Evidence for ketamine in PTSD is mixed and the drug is not FDA-approved for PTSD. Some controlled studies report symptom improvement and others do not. Trauma-focused psychotherapies remain established treatments, and any ketamine use should be discussed as an off-label option with uncertain benefit.

Are there risks of becoming dependent on ketamine therapy?

Ketamine is a Schedule III controlled substance. Prescribing should occur within an ongoing clinician-patient relationship that meets federal and state requirements, with clear dosing instructions, follow-up, misuse safeguards, and escalation pathways. FDA has specifically cautioned against compounded ketamine being used without adequate monitoring.

Selected References

• Trimmel M, et al. How do people who undergo ketamine treatment for a psychiatric problem subjectively experience this intervention? A meta-synthesis of qualitative studies. International Journal of Mental Health Nursing. 2025.

• Walaszek M, et al. Patients’ Voices on Ketamine for Treatment-Resistant Depression: A Narrative Review of Qualitative Perspectives. Journal of Clinical Medicine. 2026.

• Alnefeesi Y, et al. Real-world effectiveness of ketamine in treatment-resistant depression: systematic review and meta-analysis. Journal of Psychiatric Research. 2022.

• Simpson RJ, Juruena MF. Ketamine-assisted psychotherapy for treatment-resistant depression: systematic review. Psychopharmacology. 2026.

See how Vantage Telehealth can help — Get Started →

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, treatment, or a recommendation that ketamine is appropriate for any individual. Ketamine is a Schedule III controlled substance. Racemic ketamine is FDA-approved as an anesthetic, not for any psychiatric condition; psychiatric use is off-label. Compounded ketamine products, including compounded racemic ketamine nasal spray, are not FDA-approved or evaluated by FDA for safety, effectiveness, quality, or any psychiatric indication. Spravato® (esketamine) is a distinct FDA-approved product with specific depression-related indications and REMS requirements. Evidence, safety, dosing, and monitoring differ by route and formulation. Federal telemedicine rules for controlled-substance prescribing are time-sensitive and state law may impose additional requirements, including an in-person evaluation. Vantage Telehealth is not a medical provider; it is a technology platform that connects users with independent licensed clinicians through Impact Health USA. All prescribing and clinical decisions are made solely by the treating clinician. Vantage is not an emergency service. For a mental-health crisis or thoughts of suicide or self-harm, call or text 988. For an immediate life-threatening emergency, call 911.